Metastatic Breast Cancer - Pipeline Review, H2 2014


#235133

733pages

Global Markets Direct

$ 2000

In Stock

Metastatic Breast Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Metastatic Breast Cancer - Pipeline Review, H2 2014, provides an overview of the Metastatic Breast Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
Introduction 7
Metastatic Breast Cancer Overview 8
Therapeutics Development 9
Metastatic Breast Cancer - Therapeutics under Development by Companies 11
Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes 20
Metastatic Breast Cancer - Pipeline Products Glance 22
Metastatic Breast Cancer - Products under Development by Companies 26
Metastatic Breast Cancer - Products under Investigation by Universities/Institutes 38
Metastatic Breast Cancer - Companies Involved in Therapeutics Development 39
Metastatic Breast Cancer - Therapeutics Assessment 138
Drug Profiles 155
Metastatic Breast Cancer - Recent Pipeline Updates 515
Metastatic Breast Cancer - Dormant Projects 691
Metastatic Breast Cancer - Discontinued Products 700
Metastatic Breast Cancer - Product Development Milestones 704
Appendix 713

List of Tables
Number of Products under Development for Metastatic Breast Cancer, H2 2014 28
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2014 29
Number of Products under Development by Companies, H2 2014 31
Number of Products under Development by Companies, H2 2014 (Contd..1) 32
Number of Products under Development by Companies, H2 2014 (Contd..2) 33
Number of Products under Development by Companies, H2 2014 (Contd..3) 34
Number of Products under Development by Companies, H2 2014 (Contd..4) 35
Number of Products under Development by Companies, H2 2014 (Contd..5) 36
Number of Products under Development by Companies, H2 2014 (Contd..6) 37
Number of Products under Development by Companies, H2 2014 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H2 2014 40
Comparative Analysis by Late Stage Development, H2 2014 41
Comparative Analysis by Clinical Stage Development, H2 2014 42
Comparative Analysis by Early Stage Development, H2 2014 43
Comparative Analysis by Unknown Stage Development, H2 2014 44
Products under Development by Companies, H2 2014 45
Products under Development by Companies, H2 2014 (Contd..1) 46
Products under Development by Companies, H2 2014 (Contd..2) 47
Products under Development by Companies, H2 2014 (Contd..3) 48
Products under Development by Companies, H2 2014 (Contd..4) 49
Products under Development by Companies, H2 2014 (Contd..5) 50
Products under Development by Companies, H2 2014 (Contd..6) 51
Products under Development by Companies, H2 2014 (Contd..7) 52
Products under Development by Companies, H2 2014 (Contd..8) 53
Products under Development by Companies, H2 2014 (Contd..9) 54
Products under Development by Companies, H2 2014 (Contd..10) 55
Products under Development by Companies, H2 2014 (Contd..11) 56
Products under Investigation by Universities/Institutes, H2 2014 57
Metastatic Breast Cancer - Pipeline by AbbVie Inc., H2 2014 58
Metastatic Breast Cancer - Pipeline by Advaxis, Inc., H2 2014 59
Metastatic Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 60
Metastatic Breast Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 61
Metastatic Breast Cancer - Pipeline by AlphaVax, Inc., H2 2014 62
Metastatic Breast Cancer - Pipeline by Amarna Therapeutics B.V., H2 2014 63
Metastatic Breast Cancer - Pipeline by Amgen Inc., H2 2014 64
Metastatic Breast Cancer - Pipeline by AngioGenex, Inc., H2 2014 65
Metastatic Breast Cancer - Pipeline by Aphios Corporation, H2 2014 66
Metastatic Breast Cancer - Pipeline by Array BioPharma Inc., H2 2014 67
Metastatic Breast Cancer - Pipeline by AstraZeneca PLC, H2 2014 68
Metastatic Breast Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 69
Metastatic Breast Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 70
Metastatic Breast Cancer - Pipeline by Bayer AG, H2 2014 71
Metastatic Breast Cancer - Pipeline by BIOCAD, H2 2014 72
Metastatic Breast Cancer - Pipeline by Biocon Limited, H2 2014 73
Metastatic Breast Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 74
Metastatic Breast Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2014 75
Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 76
Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 77
Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2014 78
Metastatic Breast Cancer - Pipeline by Celgene Corporation, H2 2014 79
Metastatic Breast Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2014 80
Metastatic Breast Cancer - Pipeline by Celltrion, Inc., H2 2014 81
Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2014 82
Metastatic Breast Cancer - Pipeline by CTI BioPharma Corp., H2 2014 83
Metastatic Breast Cancer - Pipeline by Curadis GmbH, H2 2014 84
Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 85
Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 86
Metastatic Breast Cancer - Pipeline by Eisai Co., Ltd., H2 2014 87
Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H2 2014 88
Metastatic Breast Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 89
Metastatic Breast Cancer - Pipeline by Etubics Corporation, H2 2014 90
Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 91
Metastatic Breast Cancer - Pipeline by Galileo Research s.r.l., H2 2014 92
Metastatic Breast Cancer - Pipeline by Genentech, Inc., H2 2014 93
Metastatic Breast Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2014 94
Metastatic Breast Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 95
Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H2 2014 96
Metastatic Breast Cancer - Pipeline by GTx, Inc., H2 2014 97
Metastatic Breast Cancer - Pipeline by Hospira, Inc., H2 2014 98
Metastatic Breast Cancer - Pipeline by Immune Design Corp., H2 2014 99
Metastatic Breast Cancer - Pipeline by Immunomedics, Inc., H2 2014 100
Metastatic Breast Cancer - Pipeline by Immunovative Therapies, Ltd., H2 2014 101
Metastatic Breast Cancer - Pipeline by Immutep S.A., H2 2014 102
Metastatic Breast Cancer - Pipeline by Imugene Limited, H2 2014 103
Metastatic Breast Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 104
Metastatic Breast Cancer - Pipeline by Incyte Corporation, H2 2014 105
Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014 106
Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H2 2014 107
Metastatic Breast Cancer - Pipeline by Kadmon Corporation, LLC, H2 2014 108
Metastatic Breast Cancer - Pipeline by Kancera AB, H2 2014 109
Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2014 110
Metastatic Breast Cancer - Pipeline by Mabion SA, H2 2014 111
Metastatic Breast Cancer - Pipeline by MacroGenics, Inc., H2 2014 112
Metastatic Breast Cancer - Pipeline by MedImmune, LLC, H2 2014 113
Metastatic Breast Cancer - Pipeline by Merck & Co., Inc., H2 2014 114
Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 115
Metastatic Breast Cancer - Pipeline by Merus B.V., H2 2014 116
Metastatic Breast Cancer - Pipeline by MetaStat, Inc., H2 2014 117
Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 118
Metastatic Breast Cancer - Pipeline by Morphotek, Inc., H2 2014 119
Metastatic Breast Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2014 120
Metastatic Breast Cancer - Pipeline by Natco Pharma Limited, H2 2014 121
Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H2 2014 122
Metastatic Breast Cancer - Pipeline by Neopharm Ltd., H2 2014 123
Metastatic Breast Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 124
Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H2 2014 125
Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2014 126
Metastatic Breast Cancer - Pipeline by Novartis AG, H2 2014 127
Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 128
Metastatic Breast Cancer - Pipeline by OBI Pharma, Inc., H2 2014 129
Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 130
Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2014 131
Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2014 132
Metastatic Breast Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 133
Metastatic Breast Cancer - Pipeline by Pfizer Inc., H2 2014 134
Metastatic Breast Cancer - Pipeline by Pharma Mar, S.A., H2 2014 135
Metastatic Breast Cancer - Pipeline by Plexxikon Inc., H2 2014 136
Metastatic Breast Cancer - Pipeline by Polaris Group, H2 2014 137
Metastatic Breast Cancer - Pipeline by Polyphor Ltd., H2 2014 138
Metastatic Breast Cancer - Pipeline by Puma Biotechnology, Inc., H2 2014 139
Metastatic Breast Cancer - Pipeline by Recombio S.L, H2 2014 140
Metastatic Breast Cancer - Pipeline by Seattle Genetics, Inc., H2 2014 141
Metastatic Breast Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2014 142
Metastatic Breast Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 143
Metastatic Breast Cancer - Pipeline by Starpharma Holdings Limited, H2 2014 144
Metastatic Breast Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 145
Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 146
Metastatic Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 147
Metastatic Breast Cancer - Pipeline by Theracrine, Inc., H2 2014 148
Metastatic Breast Cancer - Pipeline by Transgene Biotek Limited, H2 2014 149
Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd., H2 2014 150
Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 151
Metastatic Breast Cancer - Pipeline by Wilex AG, H2 2014 152
Metastatic Breast Cancer - Pipeline by WntResearch AB, H2 2014 153
Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 154
Metastatic Breast Cancer - Pipeline by Zymeworks Inc., H2 2014 155
Metastatic Breast Cancer - Pipeline by Zyngenia, Inc., H2 2014 156
Assessment by Monotherapy Products, H2 2014 157
Assessment by Combination Products, H2 2014 158
Number of Products by Stage and Target, H2 2014 160
Number of Products by Stage and Mechanism of Action, H2 2014 166
Number of Products by Stage and Route of Administration, H2 2014 171
Number of Products by Stage and Molecule Type, H2 2014 173
Metastatic Breast Cancer Therapeutics - Recent Pipeline Updates, H2 2014 534
Metastatic Breast Cancer - Dormant Projects, H2 2014 710
Metastatic Breast Cancer - Dormant Projects (Contd..1), H2 2014 711
Metastatic Breast Cancer - Dormant Projects (Contd..2), H2 2014 712
Metastatic Breast Cancer - Dormant Projects (Contd..3), H2 2014 713
Metastatic Breast Cancer - Dormant Projects (Contd..4), H2 2014 714
Metastatic Breast Cancer - Dormant Projects (Contd..5), H2 2014 715
Metastatic Breast Cancer - Dormant Projects (Contd..6), H2 2014 716
Metastatic Breast Cancer - Dormant Projects (Contd..7), H2 2014 717
Metastatic Breast Cancer - Dormant Projects (Contd..8), H2 2014 718
Metastatic Breast Cancer - Discontinued Products, H2 2014 719
Metastatic Breast Cancer - Discontinued Products (Contd..1), H2 2014 720
Metastatic Breast Cancer - Discontinued Products (Contd..2), H2 2014 721
Metastatic Breast Cancer - Discontinued Products (Contd..3), H2 2014 722


List of Figures
Number of Products under Development for Metastatic Breast Cancer, H2 2014 28
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2014 29
Number of Products under Development by Companies, H2 2014 30
Number of Products under Investigation by Universities/Institutes, H2 2014 39
Comparative Analysis by Late Stage Development, H2 2014 41
Comparative Analysis by Clinical Stage Development, H2 2014 42
Comparative Analysis by Early Stage Products, H2 2014 43
Comparative Analysis by Unknown Stage Development, H2 2014 44
Assessment by Monotherapy Products, H2 2014 157
Number of Products by Top 10 Targets, H2 2014 159
Number of Products by Stage and Top 10 Targets, H2 2014 159
Number of Products by Top 10 Mechanism of Actions, H2 2014 165
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 165
Number of Products by Top 10 Routes of Administration, H2 2014 170
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 171
Number of Products by Top 10 Molecule Types, H2 2014 172
Number of Products by Stage and Top 10 Molecule Types, H2 2014 173

NA

NA